Screening for preclinical Alzheimer’s disease: Deriving optimal policies using a partially observable Markov model

Alzheimer’s Disease (AD) is believed to be the most common type of dementia. Even though screening for AD has been discussed widely, there is no screening program implemented as part of a policy in any country. Current medical research motivates focusing on the preclinical stages of the disease in a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Health care management science 2023-03, Vol.26 (1), p.1-20
Hauptverfasser: Önen Dumlu, Zehra, Sayın, Serpil, Gürvit, İbrahim Hakan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 20
container_issue 1
container_start_page 1
container_title Health care management science
container_volume 26
creator Önen Dumlu, Zehra
Sayın, Serpil
Gürvit, İbrahim Hakan
description Alzheimer’s Disease (AD) is believed to be the most common type of dementia. Even though screening for AD has been discussed widely, there is no screening program implemented as part of a policy in any country. Current medical research motivates focusing on the preclinical stages of the disease in a modeling initiative. We develop a partially observable Markov decision process model to determine optimal screening programs. The model contains disease free and preclinical AD partially observable states and the screening decision is taken while an individual is in one of those states. An observable diagnosed preclinical AD state is integrated along with observable mild cognitive impairment, AD and death states. Transition probabilities among states are estimated using data from Knight Alzheimer’s Disease Research Center (KADRC) and relevant literature. With an objective of maximizing expected total quality-adjusted life years (QALYs), the output of the model is an optimal screening program that specifies at what points in time an individual over 50 years of age with a given risk of AD will be directed to undergo screening. The screening test used to diagnose preclinical AD has a positive disutility, is imperfect and its sensitivity and specificity are estimated using the KADRC data set. We study the impact of a potential intervention with a parameterized effectiveness and disutility on model outcomes for three different risk profiles (low, medium and high). When intervention effectiveness and disutility are at their best, the optimal screening policy is to screen every year between ages 50 and 95, with an overall QALY gain of 0.94, 1.9 and 2.9 for low, medium and high risk profiles, respectively. As intervention effectiveness diminishes and/or its disutility increases, the optimal policy changes to sporadic screening and then to never screening. Under several scenarios, some screening within the time horizon is optimal from a QALY perspective. Moreover, an in-depth analysis of costs reveals that implementing these policies are either cost-saving or cost-effective.
doi_str_mv 10.1007/s10729-022-09608-1
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2708735899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2786335476</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-26cacb407070864ef9f529f5a6851849e05491316ec59a013d980b8b6f05c3323</originalsourceid><addsrcrecordid>eNp9kctu1TAQhi0EoqXwAiyQJTZsAuNrbHZVuUpFLIB15PhMiosTBzs5UlnxGrweT4IPKVRigayRR_Y3v2f8E_KQwVMG0D4rDFpuG-C8AavBNOwWOWaq5Y0Vxt6uuTC6sZrDEblXyiUAKNDsLjkSGqRkgh2T5YPPiFOYLuiQMp0z-him4F2kp_HbZwwj5p_ffxS6CwVdwef0BeawP_BpXsJYuTnF4AMWupbDsaOzy0twMV7R1BfMe9dHpO9c_pL2dEw7jPfJncHFgg-u9xPy6dXLj2dvmvP3r9-enZ43XhixNFx753sJbV1GSxzsoHgNp41iRloEJW2dQqNX1gETO2ugN70eQHkhuDghTzbdOaevK5alG0PxGKObMK2l41W3FcpYW9HH_6CXac1T7a5SRguhZKsrxTfK51RKxqGbc_2DfNUx6A6edJsnXfWk--1Jx2rRo2vptR9x97fkjwkVoBuAPk2h3GgaKVvJW3lAxIaUejldYL5p7z8v_wL4RaJH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2786335476</pqid></control><display><type>article</type><title>Screening for preclinical Alzheimer’s disease: Deriving optimal policies using a partially observable Markov model</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>EBSCOhost Business Source Complete</source><creator>Önen Dumlu, Zehra ; Sayın, Serpil ; Gürvit, İbrahim Hakan</creator><creatorcontrib>Önen Dumlu, Zehra ; Sayın, Serpil ; Gürvit, İbrahim Hakan</creatorcontrib><description>Alzheimer’s Disease (AD) is believed to be the most common type of dementia. Even though screening for AD has been discussed widely, there is no screening program implemented as part of a policy in any country. Current medical research motivates focusing on the preclinical stages of the disease in a modeling initiative. We develop a partially observable Markov decision process model to determine optimal screening programs. The model contains disease free and preclinical AD partially observable states and the screening decision is taken while an individual is in one of those states. An observable diagnosed preclinical AD state is integrated along with observable mild cognitive impairment, AD and death states. Transition probabilities among states are estimated using data from Knight Alzheimer’s Disease Research Center (KADRC) and relevant literature. With an objective of maximizing expected total quality-adjusted life years (QALYs), the output of the model is an optimal screening program that specifies at what points in time an individual over 50 years of age with a given risk of AD will be directed to undergo screening. The screening test used to diagnose preclinical AD has a positive disutility, is imperfect and its sensitivity and specificity are estimated using the KADRC data set. We study the impact of a potential intervention with a parameterized effectiveness and disutility on model outcomes for three different risk profiles (low, medium and high). When intervention effectiveness and disutility are at their best, the optimal screening policy is to screen every year between ages 50 and 95, with an overall QALY gain of 0.94, 1.9 and 2.9 for low, medium and high risk profiles, respectively. As intervention effectiveness diminishes and/or its disutility increases, the optimal policy changes to sporadic screening and then to never screening. Under several scenarios, some screening within the time horizon is optimal from a QALY perspective. Moreover, an in-depth analysis of costs reveals that implementing these policies are either cost-saving or cost-effective.</description><identifier>ISSN: 1386-9620</identifier><identifier>EISSN: 1572-9389</identifier><identifier>DOI: 10.1007/s10729-022-09608-1</identifier><identifier>PMID: 36044131</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Aged ; Aged, 80 and over ; Alzheimer Disease - diagnosis ; Alzheimer's disease ; Business and Management ; Cognitive ability ; Cost-Benefit Analysis ; Dementia disorders ; Econometrics ; Health Administration ; Health Informatics ; Humans ; Management ; Markov Chains ; Medical research ; Middle Aged ; Operations Research/Decision Theory ; Quality-Adjusted Life Years ; Sensitivity and Specificity</subject><ispartof>Health care management science, 2023-03, Vol.26 (1), p.1-20</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c383t-26cacb407070864ef9f529f5a6851849e05491316ec59a013d980b8b6f05c3323</cites><orcidid>0000-0001-8878-5495</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10729-022-09608-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10729-022-09608-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36044131$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Önen Dumlu, Zehra</creatorcontrib><creatorcontrib>Sayın, Serpil</creatorcontrib><creatorcontrib>Gürvit, İbrahim Hakan</creatorcontrib><title>Screening for preclinical Alzheimer’s disease: Deriving optimal policies using a partially observable Markov model</title><title>Health care management science</title><addtitle>Health Care Manag Sci</addtitle><addtitle>Health Care Manag Sci</addtitle><description>Alzheimer’s Disease (AD) is believed to be the most common type of dementia. Even though screening for AD has been discussed widely, there is no screening program implemented as part of a policy in any country. Current medical research motivates focusing on the preclinical stages of the disease in a modeling initiative. We develop a partially observable Markov decision process model to determine optimal screening programs. The model contains disease free and preclinical AD partially observable states and the screening decision is taken while an individual is in one of those states. An observable diagnosed preclinical AD state is integrated along with observable mild cognitive impairment, AD and death states. Transition probabilities among states are estimated using data from Knight Alzheimer’s Disease Research Center (KADRC) and relevant literature. With an objective of maximizing expected total quality-adjusted life years (QALYs), the output of the model is an optimal screening program that specifies at what points in time an individual over 50 years of age with a given risk of AD will be directed to undergo screening. The screening test used to diagnose preclinical AD has a positive disutility, is imperfect and its sensitivity and specificity are estimated using the KADRC data set. We study the impact of a potential intervention with a parameterized effectiveness and disutility on model outcomes for three different risk profiles (low, medium and high). When intervention effectiveness and disutility are at their best, the optimal screening policy is to screen every year between ages 50 and 95, with an overall QALY gain of 0.94, 1.9 and 2.9 for low, medium and high risk profiles, respectively. As intervention effectiveness diminishes and/or its disutility increases, the optimal policy changes to sporadic screening and then to never screening. Under several scenarios, some screening within the time horizon is optimal from a QALY perspective. Moreover, an in-depth analysis of costs reveals that implementing these policies are either cost-saving or cost-effective.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer's disease</subject><subject>Business and Management</subject><subject>Cognitive ability</subject><subject>Cost-Benefit Analysis</subject><subject>Dementia disorders</subject><subject>Econometrics</subject><subject>Health Administration</subject><subject>Health Informatics</subject><subject>Humans</subject><subject>Management</subject><subject>Markov Chains</subject><subject>Medical research</subject><subject>Middle Aged</subject><subject>Operations Research/Decision Theory</subject><subject>Quality-Adjusted Life Years</subject><subject>Sensitivity and Specificity</subject><issn>1386-9620</issn><issn>1572-9389</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kctu1TAQhi0EoqXwAiyQJTZsAuNrbHZVuUpFLIB15PhMiosTBzs5UlnxGrweT4IPKVRigayRR_Y3v2f8E_KQwVMG0D4rDFpuG-C8AavBNOwWOWaq5Y0Vxt6uuTC6sZrDEblXyiUAKNDsLjkSGqRkgh2T5YPPiFOYLuiQMp0z-him4F2kp_HbZwwj5p_ffxS6CwVdwef0BeawP_BpXsJYuTnF4AMWupbDsaOzy0twMV7R1BfMe9dHpO9c_pL2dEw7jPfJncHFgg-u9xPy6dXLj2dvmvP3r9-enZ43XhixNFx753sJbV1GSxzsoHgNp41iRloEJW2dQqNX1gETO2ugN70eQHkhuDghTzbdOaevK5alG0PxGKObMK2l41W3FcpYW9HH_6CXac1T7a5SRguhZKsrxTfK51RKxqGbc_2DfNUx6A6edJsnXfWk--1Jx2rRo2vptR9x97fkjwkVoBuAPk2h3GgaKVvJW3lAxIaUejldYL5p7z8v_wL4RaJH</recordid><startdate>20230301</startdate><enddate>20230301</enddate><creator>Önen Dumlu, Zehra</creator><creator>Sayın, Serpil</creator><creator>Gürvit, İbrahim Hakan</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>OQ6</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>L.-</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8878-5495</orcidid></search><sort><creationdate>20230301</creationdate><title>Screening for preclinical Alzheimer’s disease: Deriving optimal policies using a partially observable Markov model</title><author>Önen Dumlu, Zehra ; Sayın, Serpil ; Gürvit, İbrahim Hakan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-26cacb407070864ef9f529f5a6851849e05491316ec59a013d980b8b6f05c3323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer's disease</topic><topic>Business and Management</topic><topic>Cognitive ability</topic><topic>Cost-Benefit Analysis</topic><topic>Dementia disorders</topic><topic>Econometrics</topic><topic>Health Administration</topic><topic>Health Informatics</topic><topic>Humans</topic><topic>Management</topic><topic>Markov Chains</topic><topic>Medical research</topic><topic>Middle Aged</topic><topic>Operations Research/Decision Theory</topic><topic>Quality-Adjusted Life Years</topic><topic>Sensitivity and Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Önen Dumlu, Zehra</creatorcontrib><creatorcontrib>Sayın, Serpil</creatorcontrib><creatorcontrib>Gürvit, İbrahim Hakan</creatorcontrib><collection>ECONIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Health care management science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Önen Dumlu, Zehra</au><au>Sayın, Serpil</au><au>Gürvit, İbrahim Hakan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Screening for preclinical Alzheimer’s disease: Deriving optimal policies using a partially observable Markov model</atitle><jtitle>Health care management science</jtitle><stitle>Health Care Manag Sci</stitle><addtitle>Health Care Manag Sci</addtitle><date>2023-03-01</date><risdate>2023</risdate><volume>26</volume><issue>1</issue><spage>1</spage><epage>20</epage><pages>1-20</pages><issn>1386-9620</issn><eissn>1572-9389</eissn><abstract>Alzheimer’s Disease (AD) is believed to be the most common type of dementia. Even though screening for AD has been discussed widely, there is no screening program implemented as part of a policy in any country. Current medical research motivates focusing on the preclinical stages of the disease in a modeling initiative. We develop a partially observable Markov decision process model to determine optimal screening programs. The model contains disease free and preclinical AD partially observable states and the screening decision is taken while an individual is in one of those states. An observable diagnosed preclinical AD state is integrated along with observable mild cognitive impairment, AD and death states. Transition probabilities among states are estimated using data from Knight Alzheimer’s Disease Research Center (KADRC) and relevant literature. With an objective of maximizing expected total quality-adjusted life years (QALYs), the output of the model is an optimal screening program that specifies at what points in time an individual over 50 years of age with a given risk of AD will be directed to undergo screening. The screening test used to diagnose preclinical AD has a positive disutility, is imperfect and its sensitivity and specificity are estimated using the KADRC data set. We study the impact of a potential intervention with a parameterized effectiveness and disutility on model outcomes for three different risk profiles (low, medium and high). When intervention effectiveness and disutility are at their best, the optimal screening policy is to screen every year between ages 50 and 95, with an overall QALY gain of 0.94, 1.9 and 2.9 for low, medium and high risk profiles, respectively. As intervention effectiveness diminishes and/or its disutility increases, the optimal policy changes to sporadic screening and then to never screening. Under several scenarios, some screening within the time horizon is optimal from a QALY perspective. Moreover, an in-depth analysis of costs reveals that implementing these policies are either cost-saving or cost-effective.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>36044131</pmid><doi>10.1007/s10729-022-09608-1</doi><tpages>20</tpages><orcidid>https://orcid.org/0000-0001-8878-5495</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1386-9620
ispartof Health care management science, 2023-03, Vol.26 (1), p.1-20
issn 1386-9620
1572-9389
language eng
recordid cdi_proquest_miscellaneous_2708735899
source MEDLINE; SpringerNature Journals; EBSCOhost Business Source Complete
subjects Aged
Aged, 80 and over
Alzheimer Disease - diagnosis
Alzheimer's disease
Business and Management
Cognitive ability
Cost-Benefit Analysis
Dementia disorders
Econometrics
Health Administration
Health Informatics
Humans
Management
Markov Chains
Medical research
Middle Aged
Operations Research/Decision Theory
Quality-Adjusted Life Years
Sensitivity and Specificity
title Screening for preclinical Alzheimer’s disease: Deriving optimal policies using a partially observable Markov model
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T21%3A08%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Screening%20for%20preclinical%20Alzheimer%E2%80%99s%20disease:%20Deriving%20optimal%20policies%20using%20a%20partially%20observable%20Markov%20model&rft.jtitle=Health%20care%20management%20science&rft.au=%C3%96nen%20Dumlu,%20Zehra&rft.date=2023-03-01&rft.volume=26&rft.issue=1&rft.spage=1&rft.epage=20&rft.pages=1-20&rft.issn=1386-9620&rft.eissn=1572-9389&rft_id=info:doi/10.1007/s10729-022-09608-1&rft_dat=%3Cproquest_cross%3E2786335476%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2786335476&rft_id=info:pmid/36044131&rfr_iscdi=true